Below are the most recent publications written about "Antiretroviral Therapy, Highly Active" by people in Profiles.
-
Chatterton S, Dwyer L, Thomson C, Plit M, Longmuir H, Chaganti J, Barnett Y, Brew B. Atypical presentations and course of JC virus infection. J Neurovirol. 2022 02; 28(1):183-186.
-
Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019 02 01; 68(4):535-544.
-
Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):209-213.
-
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 05; 5(5):e211-e220.
-
Chaganti JR, Heinecke A, Gates TM, Moffat KJ, Brew BJ. Functional Connectivity in Virally Suppressed Patients with HIV-Associated Neurocognitive Disorder: A Resting-State Analysis. AJNR Am J Neuroradiol. 2017 Aug; 38(8):1623-1629.
-
Rebeiro PF, Abraham AG, Horberg MA, Althoff KN, Yehia BR, Buchacz K, Lau BM, Sterling TR, Gange SJ. Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. AIDS Patient Care STDS. 2017 Mar; 31(3):129-144.
-
Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 01; 74(2):180-184.
-
Haines CF, Fleishman JA, Yehia BR, Lau B, Berry SA, Agwu AL, Moore RD, Gebo KA. Closing the Gap in Antiretroviral Initiation and Viral Suppression: Time Trends and Racial Disparities. J Acquir Immune Defic Syndr. 2016 11 01; 73(3):340-347.
-
Patira R, Smith-Benjamin S, Wang JJ. Stroke in a young patient with neurosyphilis and HIV. Int J STD AIDS. 2017 03; 28(3):306-309.
-
Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016 09; 3(9):e410-e420.